Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SKB264 · 1 trial · 1 indication
Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
ORR is defined as the proportion of subjects with confirmed CR or PR as the best overall response assessed per RECIST 1.1.
The percentage of subjects in the analysis population who have a negative change (decrease) in PSA level of ≥ 50% measured twice ≥ 3 weeks apart
| Arm | Type | Description |
|---|---|---|
| cohort A | EXPERIMENTAL | subjects will receive SKB264 in combination with pembrolizumab by intravenous administration |
| cohort B | EXPERIMENTAL | subjects will receive SKB264 in combination with pembrolizumab by intravenous administration |
| cohort C | EXPERIMENTAL | subjects will receive SKB264 in combination with pembrolizumab by intravenous administration |
| cohort D | EXPERIMENTAL | subjects will receive SKB264 in combination with pembrolizumab by intravenous administration |
| Cohort E | EXPERIMENTAL | subjects will receive SKB264 in combination with pembrolizumab by intravenous administration |
| Name | Type | Description |
|---|---|---|
| SKB264 | DRUG | be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle; |
| Pembrolizumab | DRUG | be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle; |
Inclusion Criteria: 1. Subjects with Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 . 2. Subjects with expected survival ≥ 3 months. 3. Cohort A: Subjects with recurrent or metastatic cervical cancer 4. Cohort B: Subjects with locally advanced or metastatic urothelial ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
SKB264 is an investigational small molecule being studied for the treatment of solid tumors. It is currently in Phase 2 clinical development. The drug is being evaluated in combination with pembrolizumab in patients with selected solid tumors, as part of an active clinical trial.
SKB264 targets TROP2, a protein commonly expressed in various solid tumors. By targeting TROP2, the drug aims to deliver therapeutic effects to cancer cells. This mechanism is being investigated in the context of solid tumor treatment, though the drug remains in clinical development.
SKB264 is being developed by Myriad Genetics, Inc., a company traded on the NASDAQ under the ticker MYGN. The company is conducting a Phase 2 clinical trial to evaluate the drug in combination with pembrolizumab for selected solid tumors.
SKB264 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 2 trial is active but not recruiting participants, and it is designed to assess the drug's efficacy and safety in solid tumors.
SKB264 is being studied in a Phase 2 clinical trial with the identifier NCT05642780. This trial, titled 'SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors,' is active but not recruiting. It has an enrollment of 240 participants and is being conducted in the United States, Australia, Belgium, Canada, China, and Poland.
SKB264 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is being developed by Myriad Genetics, Inc. and is currently in Phase 2 trials for solid tumors, targeting TROP2.